Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab) dosing does not increase with patient weight. It follows a fixed schedule based on the condition being treated, administered via subcutaneous injection.[1]
- Psoriasis (plaque, ages 6+): Loading dose of 300 mg at weeks 0, 1, 2, 3, 4; then 300 mg every 4 weeks. For patients under 90 kg or children 6-17, 150 mg may be used after loading.[1]
- Psoriatic arthritis or ankylosing spondylitis: 150 mg (up to 300 mg for psoriasis overlap) at weeks 0, 1, 2, 3, 4; then every 4 weeks.[1]
- Non-radiographic axial spondyloarthritis: Same as ankylosing spondylitis.[1]
- Pediatric enthesitis-related arthritis (2+ years): 75 mg (15-50 kg) or 150 mg (>50 kg) weekly for 5 doses, then monthly.[1]
Doses are capped at 300 mg max per injection, split if needed (two 150 mg injections).[1]
Why No Weight-Based Increase?
Unlike some biologics (e.g., certain monoclonal antibodies), Cosentyx uses fixed dosing. Clinical trials showed efficacy across weight ranges without adjustments, as pharmacokinetics remain consistent in adults.[2][1] Pediatric doses scale by weight bands only to match body size in children.
What If a Patient Is Very Heavy?
No official adjustment for obesity or high weight. Real-world data and guidelines confirm standard dosing works, though exposure may vary slightly by BMI—efficacy holds.[3][1] Providers monitor response and may increase to 300 mg if suboptimal.
Comparisons to Weight-Based Biologics
| Drug | Weight-Based? | Example |
|------|---------------|---------|
| Cosentyx | No (fixed) | 150-300 mg flat |
| Stelara (ustekinumab) | Yes (partial) | 45 mg (<100 kg), 90 mg (≥100 kg) for psoriasis |
| Tremfya (guselkumab) | No | Fixed 100 mg |
| Skyrizi (risankizumab) | No | Fixed 150 mg |
Cosentyx's approach simplifies administration.[1][4]
Patient Concerns on Dosing Changes
Patients sometimes ask about increases for poor response—guidelines allow stepping up from 150 mg to 300 mg every 4 weeks, unrelated to weight.[1] No evidence supports routine weight-driven hikes.
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Approval Summary for Secukinumab
[3]: Pharmacokinetics in Obese Patients (J Clin Pharmacol, 2019)
[4]: DrugPatentWatch.com - Secukinumab Patents